SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2008 / Cilt: 50 - Sayı: 3

MIB-1, Her2/neu veya CD34 testisin evre II ve III non-seminomatöz germ hücreli tümörlerinde kullanışlı prognostik faktörler midir?

Are MIB-1, Her2/neu or CD34 useful prognostic factors in stage II and III testicular non-seminomatous germ cell tumors?

Selmin ATAERGİN
AHMET ÖZET
Fikret ARPACI
Selim KILIÇ
Önder ÖNGÜRÜ
Melih ALÖMEROĞLU
Ömer GÜNHAN
Pages
196–200
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This study revealed that MIB-1, CD34 or HER2/neu immunostaining are not good prognostic factors to predict the survival in patients with stage II and III testicular non-seminomatous germ cell tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study we analyzed immunocytochemical expression of MIB-1, HER2/neu and CD34 in stage II and III testicular non-seminomatous germ cell tumors to investigate if these factors may be useful in determining the prognosis of the disease.
📊
Key Findings & Data:Orchiectomy specimens of 64 patients were studied for MIB-1, HER2/neu and CD34 immunostaining.
💡
Conclusion & Impact:This study revealed that MIB-1, CD34 or HER2/neu immunostaining are not good prognostic factors to predict the survival in patients with stage II and III testicular non-seminomatous germ cell tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Neoplazm evrelendirilmesi · Neoplazmlar · germ hücreli ve embriyonel

Abstract

In this study we analyzed immunocytochemical expression of MIB-1, HER2/neu and CD34 in stage II and III testicular non-seminomatous germ cell tumors to investigate if these factors may be useful in determining the prognosis of the disease. Orchiectomy specimens of 64 patients were studied for MIB-1, HER2/neu and CD34 immunostaining. In 47% and 30% of the cases MIB-1 immunostaining level was under the median value in patients with stage II and III disease, respectively. The intensity of immunostaining with CD34 was (+) in 31% of the cases, (++) in 40% of the cases and (+++) in 29% of the cases in stage II tumors. The intensity of CD34 immunostaining was (++) in 26% and (+++) in 73% of the patients with stage III tumors. None of the specimens were stained with HER2/neu. The intensity of CD34 and MIB-1 immunostaining increased with advancing stage. This study revealed that MIB-1, CD34 or HER2/neu immunostaining are not good prognostic factors to predict the survival in patients with stage II and III testicular non-seminomatous germ cell tumors.

Özet

Bu çalışmada MIB-1, HER2/neu ve CD34 immünhistokimyasal ekspresyonunun testisin evre II ve III non-seminomatöz germ hücreli tümörlerinde ekspresyonuna bakarak, bu faktörlerin hastalığın prognozunu belirlemede yardımcı olup olamayacağını araştırdık. Altmış dört hastaya ait orşiektomi örnekleri MIB-1, HER2/neu ve CD34 immün boyanma ile incelendi. Olguların sırasıyla %47 ve %30'unda immün boyanma düzeyi evre II ve III olgularda medyan değerin altında bulundu. CD34 ile immün boyanma yoğunluğu evre II olguların %31'inde (+), %40'ında (++) ve %29'unda (+++) olarak bulundu. CD34 immün boyanma yoğunluğu evre III olguların %26'sında (++) ve %73'ünde (+++) olarak bulundu. Örneklerin hiçbirisi HER2/neu ile boyanma göstermedi. CD34 ve MIB-1 immün boyanma yoğunluğu ilerleyen evreyle birlikte artış göstermiştir. Bu çalışma MIB-1, CD34 veya HER2/neu immün boyanmasının evre II ve III testis non-seminomatöz germ hücreli tümör olgularında sağkalımı göstermede iyi birer prognostik faktör olmadığını göstermiştir.

🔖

Cite This Article

ATAERGİN, S., ÖZET, A., ARPACI, F., KILIÇ, S., ÖNGÜRÜ, Ö., ALÖMEROĞLU, M., GÜNHAN, Ö. (2008). MIB-1, Her2/neu veya CD34 testisin evre II ve III non-seminomatöz germ hücreli tümörlerinde kullanışlı prognostik faktörler midir?. Gülhane Tıp Dergisi, Cilt: 50 - Sayı: 3, 196–200. https://ajindex.com/articles/226178

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Suita S, Shono K, Tajiri T, et al. Malignant germ cell tumors: clinical characteristics, treatment and outcome. A report from the study group for pediatric solid malignant tumors in the Kyushu Area, Japan. J Pediatr Surg 2002; 37: 1703-1706
  2. Bhatia S, Abanour R, Porcu P. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18: 3346-3351
  3. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferationassociated human nuclear antigen defined by monoclonal antibody ki-67. J Immunol 1984; 133:1710-1715
  4. Falini B, Flenghi L, Fagioli M. Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognised by the ki- 67 monoclonal antibody. J Histochem Cytochem 1986;37: 1471-1476
  5. Leonardi E, Girlando S, Serio G, Mauri FA, Perrone G, Scampini S. DNA and ki-67 expression in breast carcinoma: correlation with clinical and biological variables. J Clin Pathol 1992; 45: 416-421
  6. Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RR, Fazio VW. ki-67 determined growth fraction versus standard staging and grading parameters in colorectal carcinoma: a multivariate analysis. Cancer 1992; 70:2602-2610
  7. Sadi MV, Barrack ER. Determination of growth fraction in advanced prostate cancer by ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer 1991; 67: 3065-3072
  8. Albers P, Bierhoff E, Neu D, Fimmers R, Wernert N, Müller SC. MIB-1 immunohistochemistry in clinical stage I non-seminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 1997;79: 1710-1716
  9. Aaronson SA. Growth factors and cancer. Science 1991;254: 1146-1153
  10. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996; 87:1-13
  11. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997; 33: 369-374
  12. Van de Rijn M, Rouse RV. CD 34: a review. Appl Immunohistochem 1994; 2: 71-80
  13. Suster S. Recent advances in the application of immunocytochemical markers for the diagnosis of soft tissue tumors. Semin Diagn Pathol 2000; 17: 225-235
  14. Shah VI, Amin MB, Linden MD, Zarbo RJ. Utility of a selective immunocytochemical panel in the detection of components of mixed germ cell tumors of testis. Mod Pathol 1998; 11